

Electronic Supplementary Material

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Development of a dual temperature control system for isoprene biosynthesis in *Saccharomyces cerevisiae*

Jiaxi Lin¹, Zhen Yao³, Xiaomei Lyu⁴, Lidan Ye (✉)^{1,2}, Hongwei Yu (✉)¹

1 Institute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China

2 Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311200, China

3 Key Laboratory of Systems Microbial Biotechnology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China

4 School of Food Science and Technology, Jiangnan University, Wuxi 214122, China

E-mails: yelidan@zju.edu.cn (Ye L); yuhongwei@zju.edu.cn (Yu H)

Table S1 Yeast strains used or constructed in this study

Strain	Genotype/Description	Plasmid	Reference
BY4741	<i>MATα, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0</i>	None	[1]
BY4742	<i>MATα, his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0</i>	None	[1]
YXWP-113	BY4741, Δ <i>gal80::LEU2</i>	None	[2]
YXWP-111	YXWP-113, <i>Δho::T_{TPSI}-tHMG1-P_{GAL7}-P_{GAL2}-crtYB11M-T_{PGK1}-T_{CYC1}-crtI-P_{GALI}-P_{GAL10}-crtE03M-T_{ADH1}</i>	None	[2]
YEGFP-TS0	YXWP-113, Δ <i>gal4::HIS3</i>	None	[3]
YCS113-URA	YEGFP-TS0, <i>Δho::T_{ADH1}-MCS1-P_{GAL10}-P_{GALI}-URA3-T_{CYC1}</i>	None	This study
Y113EGFP-0	YXWP-113	pESC-URA-P _{ERG9} -EGFP	This study
Y113EGFP-1	YXWP-113	pESC-URA-1HSE-EGFP	This study
Y113EGFP-2	YXWP-113	pESC-URA-2HSE-EGFP	This study
Y113EGFP-S	YXWP-113	pESC-URA-SSA4-EGFP	This study
Yelacz	YEGFP-TS0, <i>Δdpp1::T_{ADH1}-EGFP-P_{GAL10}-P_{GALI}-LacZ-T_{CYC1}</i>	None	This study
Yelacz-ERG9-WT	Yelacz	pESC-URA-P _{ERG9} -GAL4	This study
Yelacz-SSA4-WT	Yelacz	pESC-URA-P _{SSA4} -GAL4	This study
BY4742-M-04-HIS	BY4742, <i>his3::HIS3, Δlpp1::T_{CYC1}-ERG10-MLS-P_{GALI}-P_{GAL10}-MLS-HMGS-T_{ADH1},</i> <i>Δho::T_{TPSI}-tHMG1-MLS-P_{GAL7}-P_{GAL2}-MLS-ERG12-T_{PGK1},</i> <i>Δdpp1::T_{CYC1}-tHMG1-MLS-P_{GALI}-P_{GAL10}-MLS-PMK-T_{ADH1},</i> <i>Δgal80::T_{TPSI}-MVD1-MLS-P_{GAL7}-P_{GAL2}-MLS-IDII-T_{PGK1},</i>	None	[4]
BY4742-M-04-GAL4-HIS	BY4742-M-04-HIS, <i>Δgal1-7::P_{GAL4}-GAL4-T_{CYC1}</i>	None	This study
BY4742-M-08-HIS3	BY4742-M-04-HIS3, <i>Δura3::T_{ADH1}-MVD1-MLS-P_{GAL10}-P_{GALI}-MLS-IDII-T_{CYC1}</i> <i>Δlys2::T_{ADH1}-MCS-P_{GAL10}-P_{GALI}-MLS-IDII-T_{CYC1}</i>	None	[4]
M08H-CS	BY4742-M-08-HIS3, <i>Δgal4::LEU2</i>	None	This study
M08H-CS-MLN-WT	M08H-CS	p416XWP01- <i>MLSLN-GAL4WT</i>	This study
M08H-CS-MLN-ep19	M08H-CS	p416XWP01- <i>MLSLN-GAL4ep19</i>	This study

M08H-CS-MLN-SSA4-WT	M08H-CS	p416XWP01- <i>MLSLN</i> -P _{SSA4} - <i>GAL4</i> WT	This study
M08H-CS-MLN-SSA4-ep19	M08H-CS	p416XWP01- <i>MLSLN</i> -P _{SSA4} - <i>GAL4</i> ep19	This study

25
26
27
28


Table S2 Primers used in this study

Primer name	Primer sequence	Description
URA3-LF	<u>CGGGATCC</u> ATGTCGAAAGCTACATATAAGG	Amplify <i>URA3</i> and facilitate its insertion into pMRI-31
URA3-LR	G <u>CGTCGAC</u> TTAGTTTTGCTGGCCGCATC	
ERG9-F2	GAAGAGCAGAAGCGGAAAAC	For Gal4p mutants library construction
GAL4-DR1	TTGTGAAAACCTGTAAGAGCC	
MET15nheI-F	CTAG <u>CTAGC</u> CAACAATTAATCCAAGTTCACCTATTCTG	Amplify <i>MET15</i> and facilitate its insertion into p416XWP-P _{ERG9} - <i>GAL4</i>
MET15sacII-R	TCC <u>CCGCGGGG</u> GATGACTAATTAAGTTAGTCAAGGCGCCA	
GAL4-LEU2XF1	CTATCCGTAATCATGGTCGGTTAAGCAAGGATTTTCTTAA	For construction of <i>GAL4</i> disruption cassette
GAL4-LEU2XR1	GCCTTTTTCTGTTTTATGAGCTAAACTGTGGGAATACTCAGGT	
LEU2XF2	ACCTGAGTATTCACAGTTTAGCTCATAAAACAGAAAAGGC	
GAL4-XinR	AACCCAGAATCCCCTATACTAA	
GAL4-LEU2-R1	TTAAGAAAATCCTTGCTTAACCGACCATGATTACGGATAG	
GAL4-XinF1	AATTGGATCTCCCAAGAGTA	
Perg9416ecor-F1	GCCGCCCTTTAGTGAGGGTT <u>GAATTC</u> TGTGTGTGTGATATGTGACG	Amplify P _{ERG9} -P _{GALI} bidirectional promoter
Perg9-gal1-R1	GCAGTGCGGCGCGAGGCACACGCTCTAACTCCGCAGGAAC	
Pgal1-ERG9-F1	GTTCTGCGGAGTTAGAGCGTGTGCCTCGCGCCGCACTGC	Amplify <i>MLS-ISP</i> <i>SLN</i> fragment
Pgal141601-R1	CCTATAGTGAGTCGTATTAC <u>GGATCC</u> GGGTTTTTTCTCCTTGACGTTAA	
MLS26sal1-F1	CTCACTATAGGGCCCGGGC <u>GTCGAC</u> ATGCTTTCCTACTACGTC AATCTATAAG	
ISPhind3-R1	CTTAGCTAGCCGCGGTACCA <u>AGCT</u> TTTATCTTTTCGAATG	Amplify P _{SSA4} -P _{GALI} bidirectional promoter
PQ-NotI-R	AGTC <u>GCGGCCG</u> GATTATTGTTTTGTTATTTTTTTCTTGTTTTGTTATTAC	

PQ-speI-Pgal1-F'	CAGTGCGGCGCGAGGCACA <u>ACTAGT</u> AGATCTGCTAATATATTTTACGTAAGATTCGTTG	
PGAL1-speI-PQ-F	CTTACGTAAAATATATTAGCAGATCT <u>ACTAGT</u> TGTGCCTCGCGCCGCACTGCTCC	
PGAL1-smaI-R	ACTG <u>CCCCGGG</u> GTTTTTCTCCTTGACGTTAAAGTATAGAGGTATATTAAC	
PIHSE-NOTI-R	GAAGACAGTAGCTTCAT <u>GCGGCCG</u> CGATTATTGTTTTGTTTATTTTTTTCTTG	
BAMH-1HSE-F	CCTATAGTGAGTCGTATTAC <u>GATCC</u> GAAAGCTCCTTAGTTTGACGACAG	Amplify P _{SSA4-1} , P _{SSA4-2} , P _{SSA4} promoters to facilitate insertion
BAMH-2HSE-F	CCTATAGTGAGTCGTATTAC <u>GATCC</u> GAGCAATGAAGTACATTCTAGAAGTTC	into pESC-URA
QUETA-BamH1-F	CTATAGTGAGTCGTATTAC <u>GATCC</u> AGATCTGCTAATATATTTTACGTAAGATTCGTTG	
lacZ-BamHI-F	CAAGGAGAAAAA <u>ACCCCGATCC</u> ATGACCATGATTACGGATTCACTGG	Amplify <i>LacZ</i> to facilitate insertion into
lacZ-SacII-R	GAGCGGATCTTAGCTAG <u>CCGCGG</u> TTATTTTTGACACCAGACCAACTGGTAATG	pUMRI-11-EGFP-LacZ


29 **Table S3** Plasmids used or constructed in this study

Plasmids	Genotype/Description	Reference
pESC-LEU	<i>fl ori</i> , 2μ <i>ori</i> , <i>LEU2</i> , <i>Amp</i> , <i>TADHI-MCS1-P_{GALI0}-P_{GALI}-MCS2-TCYCI</i>	Agilent Technologies
pMRI-31	<i>TADHI-MCS1-P_{GALI0}-P_{GALI}-MCS2-TCYCI</i> , <i>HO</i> homologous arm	[5]
pMRI-31-URA3	<i>TADHI-MCS1-P_{GALI0}-P_{GALI}-URA3-TCYCI</i> , <i>HO</i> homologous arm	This study
p416XWP- <i>P_{ERG9}-GAL4</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>P_{ERG9}-GAL4-TADHI</i>	[3]
p416xwp- <i>MET-P_{ERG9}-GAL4</i>	<i>CEN/ARS</i> , <i>Met15</i> , <i>P_{ERG9}-GAL4-TADHI</i>	This study
p416XWP01	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-MCS1-P_{GALI0}-P_{GALI}-MCS2-TCYCI</i>	[6]
p416XWP01- <i>MISPSLN</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-MCS1-P_{GALI0}-P_{GALI}-MLS-ISPSLN-TCYCI</i>	[4]
p416XWP01- <i>P_{ERG9}</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-MCS1-P_{ERG9}-P_{GALI}-MCS2-TCYCI</i>	This study
p416XWP01- <i>MLSLN-P_{ERG9}</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-MCS1-P_{ERG9}-P_{GALI}-MLS-ISPSLN-TCYCI</i>	This study
p416XWP01- <i>MLSLN-GAL4WT</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-GAL4WT-P_{ERG9}-P_{GALI}-MLS-ISPSLN-TCYCI</i>	This study
p416XWP01- <i>MLSLN-GAL4ep19</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-GAL4ep19-P_{ERG9}-P_{GALI}-MLS-ISPSLN-TCYCI</i>	This study
p416XWP01- <i>MLSLN-P_{SSA4}-GAL4ep19</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-GAL4ep19-P_{SSA4}-P_{GALI}-MLS-ISPSLN-TCYCI</i>	This study
p416XWP01- <i>MLSLN-P_{SSA4}-GAL4WT</i>	<i>CEN/ARS</i> , <i>URA3</i> , <i>TADHI-GAL4WT-P_{SSA4}-P_{GALI}-MLS-ISPSLN-TCYCI</i>	This study
pESC-URA	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>TADHI-MCS1-P_{GALI0}-P_{GALI}-MCS2-TCYCI</i>	GenBank: AF063585
pESC-URA- <i>P_{ERG9}</i>	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{ERG9}-MCS-TADHI</i>	This study
pESC-URA- <i>P_{ERG9}-EGFP</i>	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{ERG9}-EGFP-TADHI</i>	This study
pESC-URA-1HSE-EGFP	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{1HSE}-EGFP-TADHI</i>	This study
pESC-URA-2HSE-EGFP	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{2HSE}-EGFP-TADHI</i>	This study
pESC-URA- <i>SSA4-EGFP</i>	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{SSA4}-EGFP-TADHI</i>	This study
pESC-URA- <i>P_{ERG9}-GAL4</i>	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{ERG9}-GAL4-TADHI</i>	This study
pESC-URA- <i>P_{SSA4}-GAL4</i>	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{SSA4}-GAL4-TADHI</i>	This study
pESC-URA- <i>P_{SSA4}-GAL4ep19</i>	<i>fl ori</i> , 2μ <i>ori</i> , <i>URA3</i> , <i>Amp</i> , <i>P_{SSA4}-GAL4ep19-TADHI</i>	This study
pUMRI-11-EGFP	<i>TADHI-EGFP-P_{GALI0}-P_{GALI}-MCS2-TCYCI</i> , <i>DPP1</i> homologous arm	[3]
pUMRI-11-EGFP-LacZ	<i>TADHI-EGFP-P_{GALI0}-P_{GALI}-LacZ-TCYCI</i> , <i>DPP1</i> homologous arm	This study




30

31 **Fig. S1** Effect of *GAL4* overexpression on biomass. The effect of *GAL4* overexpression on biomass in strain
 32 BY4742-M-04-HIS [7] harboring a mitochondrial isoprene synthetic pathway. The data presented are the means of
 33 three biological replicates. Error bars represent the standard deviations.




34

35 **Fig. S2** Effect of temperature on isoprene production and cell growth. The effects of temperature (30 °C, 35 °C,
 36 37 °C) on isoprene production and cell growth. The data presented are the means of three biological replicates.




37

38 **Fig. S3** Biosynthesis of lycopene in engineered yeast at different temperatures. Strain Yxwp111 expressing the
 39 lycopene pathway grown at 30 °C, 30 °C/37 °C, 37 °C respectively.




40

41 **Fig. S4** Isoprene production and growth of strains expressing Gal4p variants with single-point mutations. (a) The
 42 growth of strains expressing Gal4p with single-point mutations. (b) The isoprene production of strains expressing
 43 Gal4p with single-point mutations. Wild-type Gal4p, Gal4ep19 and Gal4p variants carrying T262A, M265T,
 44 N308D, R378G single mutations were transformed respectively into M08H-CS. The isoprene production and
 45 biomass were compared after 48 h of shake-flask fermentation. Cells were cultured in sealed vials. The data
 46 presented are the means of three biological replicates. Error bars represent the standard deviations. Significant
 47 levels of t-test: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.



48

49 **Fig. S5** Aerobic batch fermentation of strain M08H-CS-MLN-WT at different temperatures. The isoprene
 50 production and biomass were compared when cultured at 30 °C, 30 °C/37 °C, 37 °C after 72 h of aerobic batch
 51 fermentation. Green arrow indicated the time point of temperature shift from 30 °C to 37 °C. (a) Biomass of strain
 52 M08H-CS-MLN-WT at different temperatures. (b) The isoprene production of strain M08H-CS-MLN-WT at
 53 different temperatures.



54

55 **Fig. S6** Sugar consumption during aerobic batch fermentation of recombinant yeast strains. The arrows indicated
56 the time points of temperature shift from 30 °C to 37 °C.

57 **References**

- 58 1. Brachmann C B, Davies A, Cost G J, Caputo E, Li J, Hieter P, Boeke J D. Designer deletion strains
59 derived from *Saccharomyces cerevisiae* S288C: a useful set of strains and plasmids for PCR-mediated
60 gene disruption and other applications. *Yeast*, 1998, 14(2): 115-132
- 61 2. Xie W P, Lv X M, Ye L D, Zhou P P, Yu H W. Construction of lycopene-overproducing
62 *Saccharomyces cerevisiae* by combining directed evolution and metabolic engineering. *Metabolic*
63 *Engineering*, 2015, 30: 69-78
- 64 3. Zhou P P, Xie W P, Yao Z, Zhu Y Q, Ye L D, Yu H W. Development of a temperature-responsive
65 yeast cell factory using engineered Gal4 as a protein switch. *Biotechnology and Bioengineering*, 2018,
66 115(5): 1321-1330
- 67 4. Yao Z, Zhou P P, Su B M, Su S S, Ye L D, Yu H W. Enhanced isoprene production by reconstruction
68 of metabolic balance between strengthened precursor supply and improved isoprene synthase in
69 *Saccharomyces cerevisiae*. *ACS Synthetic Biology*, 2018, 7(9): 2308-2316
- 70 5. Xie W P, Liu M, Lv X M, Lu W Q, Gu J L, Yu H W. Construction of a controllable beta-carotene
71 biosynthetic pathway by decentralized assembly strategy in *Saccharomyces cerevisiae*. *Biotechnology*
72 *and Bioengineering*, 2014, 111(1): 125-133
- 73 6. Xie W P, Ye L D, Lv X M, Xu H M, Yu H W. Sequential control of biosynthetic pathways for
74 balanced utilization of metabolic intermediates in *Saccharomyces cerevisiae*. *Metabolic Engineering*,
75 2015, 28: 8-18
- 76 7. Lv X M, Wang F, Zhou P P, Ye L D, Xie W P, Xu H M, Yu H W. Dual regulation of cytoplasmic and
77 mitochondrial acetyl-CoA utilization for improved isoprene production in *Saccharomyces cerevisiae*.
78 *Nature Communications*, 2016, 7: 12851